Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
ALMS · Why this verdict
Why Alumis (ALMS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The entire commercial prospect depends on one drug candidate; there is no secondary revenue stream to absorb setbacks if that program encounters clinical or regulatory difficulty, leaving the investment exposed to a single binary outcome. Bear case | A second clinical-stage program is announced or a partnership transaction is disclosed within 12 months, materially reducing single-asset dependence. | →Stable |
| CounterA focused single-asset strategy can accelerate regulatory timelines and concentrate management attention; some of the most consequential biotech returns have come from precisely this kind of concentrated bet, where breadth would have diluted the core opportunity. | ||
Free cash flow is deeply negative at more than twenty-four times annual revenue, the business has no identifiable competitive moat, and the financial health score stands at three out of nine — placing fundamental quality well below any threshold consistent with a sustainable enterprise. Quality breakdown | Cash burn narrows meaningfully relative to revenue as the company approaches commercial milestones, with the financial health score improving to at least five out of nine. | →Stable |
| CounterPre-commercial biotechs are structurally expected to burn cash; quality metrics at this development stage reflect investment-phase economics rather than the potential commercial franchise value that successful clinical outcomes could unlock. | ||
After two consecutive earnings misses, the company delivered back-to-back beats in its two most recent quarters — the latest coming in 4% ahead of estimates following a dramatic 74% upside surprise the prior quarter — suggesting that cost management around clinical milestones may be stabilizing. Earnings | The beat streak extends to three or more consecutive quarters over the next 12 months, reinforcing the execution inflection. | →Stable |
| CounterTwo beats against deeply negative estimates are easy to produce by deferring spending; the prior miss history — two of the four quarters in the window — reveals inconsistency, and the large prior-quarter surprise may simply reflect a one-time estimate reset rather than durable guidance discipline. | ||
Short interest stands at 15% of float and the put/call ratio is 4.06, reflecting heavily one-sided bearish positioning that could produce a sharp upward move if clinical data surprises favorably, but equally signals that informed capital is firmly positioned against the thesis. Risk breakdown | Short interest declines below 10% of float within 12 months following a positive catalyst, indicating the bearish crowd is being forced to cover. | →Stable |
| CounterHigh short interest at this level may be entirely rational — professional investors pricing binary clinical risk on a cash-burning, single-asset company with no competitive moat and a 256% implied volatility environment. | ||
The entire commercial prospect depends on one drug candidate; there is no secondary revenue stream to absorb setbacks if that program encounters clinical or regulatory difficulty, leaving the investment exposed to a single binary outcome.
→StableBear case
- Expectation
- A second clinical-stage program is announced or a partnership transaction is disclosed within 12 months, materially reducing single-asset dependence.
CounterA focused single-asset strategy can accelerate regulatory timelines and concentrate management attention; some of the most consequential biotech returns have come from precisely this kind of concentrated bet, where breadth would have diluted the core opportunity.
Free cash flow is deeply negative at more than twenty-four times annual revenue, the business has no identifiable competitive moat, and the financial health score stands at three out of nine — placing fundamental quality well below any threshold consistent with a sustainable enterprise.
→StableQuality breakdown
- Expectation
- Cash burn narrows meaningfully relative to revenue as the company approaches commercial milestones, with the financial health score improving to at least five out of nine.
CounterPre-commercial biotechs are structurally expected to burn cash; quality metrics at this development stage reflect investment-phase economics rather than the potential commercial franchise value that successful clinical outcomes could unlock.
After two consecutive earnings misses, the company delivered back-to-back beats in its two most recent quarters — the latest coming in 4% ahead of estimates following a dramatic 74% upside surprise the prior quarter — suggesting that cost management around clinical milestones may be stabilizing.
→StableEarnings
- Expectation
- The beat streak extends to three or more consecutive quarters over the next 12 months, reinforcing the execution inflection.
CounterTwo beats against deeply negative estimates are easy to produce by deferring spending; the prior miss history — two of the four quarters in the window — reveals inconsistency, and the large prior-quarter surprise may simply reflect a one-time estimate reset rather than durable guidance discipline.
Short interest stands at 15% of float and the put/call ratio is 4.06, reflecting heavily one-sided bearish positioning that could produce a sharp upward move if clinical data surprises favorably, but equally signals that informed capital is firmly positioned against the thesis.
→StableRisk breakdown
- Expectation
- Short interest declines below 10% of float within 12 months following a positive catalyst, indicating the bearish crowd is being forced to cover.
CounterHigh short interest at this level may be entirely rational — professional investors pricing binary clinical risk on a cash-burning, single-asset company with no competitive moat and a 256% implied volatility environment.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Alumis is a pre-commercial biotech whose investment case rests entirely on a single pipeline candidate while burning cash at a rate far exceeding revenue; although price momentum is constructive and analyst price targets imply substantial upside, deep quality concerns — no competitive moat, a failing financial-health screen, and extreme bearish positioning in both the short book and options market — place this firmly in speculative territory pending clinical proof.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.5 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Rule of 40 | 3.0 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -2461% of revenue
- ▸No competitive moat
- ▸Rule of 40: -2551 (fail)
- ▸Weak Piotroski F-Score: 3/9
Growth
5.0/10data confidence 50%Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.1 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.2 |
| Price target | 9.4 |
| erm sentiment | 4.5 |
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 47%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
2.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 1.5 |
| growth rank | 0.6 |
Technical
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.9 |
| support resistance | 1.3 |
| 52w position | 7.8 |
Risk (lower is worse)
0.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.7 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 2.1 |
| implied vol | 0.0 |
| debt equity | 0.0 |
- ▸High short interest justified: 18%
- ▸Elevated put/call: 1.68
- ▸High IV: 100%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 9.5 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:7.2>=5.5
- ASYMMETRY:1.9>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:38d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
1.86
Upside
+27.9%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 65, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 7.6, and Momentum at 7.2; the weakest are Risk (lower is worse) at 0.6, Peer rank at 2.0, and Quality at 2.9. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 1.86 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Pipeline Concentration Risk
Trip ifFewer than 2 programs reach Phase 2 or later within 12 months, leaving the single-asset concentration intact.
- P2Cash Burn No Moat Quality Failure
Trip ifFCF burn rate improves to less than -500% of revenue for 2 consecutive quarters.
- P3Recent Earnings Beat Inflection
Trip ifEPS surprise falls below 0% in either of the next 2 reported quarters.
- P4Extreme Bearish Options Short Positioning
Trip ifShort interest falls below 8% of float for 2 consecutive months, indicating the bearish crowd has cleared.